Omesdafexor

• CAT Number: I043394
• CAS Number: 2244440-85-3
• Molecular Formula: C34H43N3O3
• Molecular Weight: 541.72
• Purity: ≥95%
• Synonyms: N-[3-(1-cyclopropylpyrazol-4-yl)phenyl]-4-hydroxy-N-[[4-(4-methoxy-3-methylphenyl)cyclohexyl]methyl]cyclohexane-1-carboxamide
• InChI: InChI=1S/C34H43N3O3/c1-23-18-28(12-17-33(23)40-2)25-8-6-24(7-9-25)21-36(34(39)26-10-15-32(38)16-11-26)31-5-3-4-27(19-31)29-20-35-37(22-29)30-13-14-30/h3-5,12,17-20,22,24-26,30,32,38H,6-11,13-16,21H2,1-2H3
• InChIKey: RPBNLMPTFCTXRQ-UHFFFAOYSA-N
• SMILES: CC1=C(C=CC(=C1)C2CCC(CC2)CN(C3=CC=CC(=C3)C4=CN(N=C4)C5CC5)C(=O)C6CCC(CC6)O)OC

Omesdafexor（Cat No.:I043394）is an investigational small-molecule compound being studied for its potential use in treating liver diseases, particularly non-alcoholic steatohepatitis (NASH). It acts as a selective inhibitor of the farnesoid X receptor (FXR), a nuclear receptor involved in regulating bile acid synthesis, lipid metabolism, and inflammation. By modulating FXR activity, Omesdafexor aims to reduce liver inflammation, fibrosis, and other metabolic disturbances associated with NASH and other chronic liver conditions. Preclinical and clinical studies are exploring its efficacy and safety, offering potential as a novel therapeutic option for patients with liver diseases.